Thrivent Financial for Lutherans
ALXN

Thrivent Financial for Lutherans’s Alexion Pharmaceuticals ALXN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,493
Closed -$1.74M – 2523
2021
Q2 		$1.74M Buy
9,493
+67
+0.7% +$11.5K ﹤0.01% 1500
2021
Q1 		$1.44M Sell
9,426
-411,575
-98% -$63.7M ﹤0.01% 1626
2020
Q4 		$65.8M Sell
421,001
-168,087
-29% -$21.6M 0.15% 171
2020
Q3 		$67.4M Buy
589,088
+97,758
+20% +$10.5M 0.18% 135
2020
Q2 		$55.1M Sell
491,330
-21,210
-4% -$2.25M 0.17% 152
2020
Q1 		$46M Sell
512,540
-31,765
-6% -$3.12M 0.17% 154
2019
Q4 		$58.9M Buy
544,305
+491,787
+936% +$52.6M 0.17% 166
2019
Q3 		$5.14M Buy
52,518
+42,450
+422% +$4.78M 0.02% 681
2019
Q2 		$1.32M Buy
10,068
+91
+0.9% +$11.7K ﹤0.01% 1230
2019
Q1 		$1.35M Buy
9,977
+252
+3% +$31.3K ﹤0.01% 1176
2018
Q4 		$947K Buy
9,725
+171
+2% +$20.2K ﹤0.01% 1189
2018
Q3 		$1.33M Buy
9,554
+211
+2% +$26.5K ﹤0.01% 1110
2018
Q2 		$1.16M Sell
9,343
-920,479
-99% -$108M ﹤0.01% 1170
2018
Q1 		$104M Sell
929,822
-56,004
-6% -$6.69M 0.35% 61
2017
Q4 		$118M Buy
985,826
+177,594
+22% +$21.6M 0.39% 54
2017
Q3 		$113M Sell
808,232
-43,934
-5% -$5.97M 0.4% 53
2017
Q2 		$104M Buy
852,166
+132,456
+18% +$15.4M 0.43% 51
2017
Q1 		$87.3M Sell
719,710
-318,110
-31% -$41M 0.38% 63
2016
Q4 		$127M Buy
1,037,820
+129,890
+14% +$15.9M 0.57% 33
2016
Q3 		$111M Buy
907,930
+283,070
+45% +$36.4M 0.51% 36
2016
Q2 		$73M Buy
624,860
+618,320
+9,454% +$87.7M 0.35% 71
2016
Q1 		$910K Buy
6,540
+210
+3% +$30.8K ﹤0.01% 1111
2015
Q4 		$1.21M Sell
6,330
-698,880
-99% -$122M 0.01% 1007
2015
Q3 		$110M Sell
705,210
-72,680
-9% -$13.3M 0.58% 36
2015
Q2 		$141M Buy
777,890
+336,510
+76% +$58.1M 0.78% 23
2015
Q1 		$76.5M Buy
441,380
+436,680
+9,291% +$79M 0.42% 57
2014
Q4 		$870K Sell
4,700
-26,700
-85% -$4.95M ﹤0.01% 884
2014
Q3 		$5.21M Buy
31,400
+26,700
+568% +$4.38M 0.03% 455
2014
Q2 		$734K Buy
4,700
+100
+2% +$15.8K ﹤0.01% 982
2014
Q1 		$700K Hold
4,600
– – ﹤0.01% 826
2013
Q4 		$611K Hold
4,600
– – ﹤0.01% 901
2013
Q3 		$534K Sell
4,600
-2,200
-32% -$241K ﹤0.01% 903
2013
Q2 		$627 Buy
+6,800
New +$655K ﹤0.01% 832

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Thrivent Financial for Lutherans's ALXN Position: Q3 2021 in Review

Thrivent Financial for Lutherans sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,493 shares — an estimated $1.74M sold.

Thrivent Financial for Lutherans first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $141M in Q2 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Thrivent Financial for Lutherans reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 9,493 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.74M.
  • Thrivent Financial for Lutherans first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Thrivent Financial for Lutherans's Alexion Pharmaceuticals position peaked at $141M in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2021, filed 15 Nov 2021.